Riassunto: BeOne Medicines annuncia i risultati positivi di fase 3 per BRUKINSA, come trattamento di prima linea per il linfoma a cellule mantellari (MCL)
Wednesday, July 1, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: BeOne Medicines has reported positive results from a Phase 3 trial of BRUKINSA, indicating its effectiveness as a first-line treatment for mantle cell lymphoma (MCL). This development could significantly enhance treatment options for patients with MCL. The results are expected to impact future treatment protocols.
Price reaction · baseline $284.97 (2026-06-30 close) · hit after-hours · clean, no other ONC news in the window
BRUKINSA shows efficacy as a first-line treatment.
Potential to improve patient outcomes in MCL.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
Tislelizumab
Phase 3 · Non-small Cell Lung Cancer
Full Press Release Details
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd.(Nasdaq: ONC; HKEX: 06160; SSE: 688235), un'azienda oncologica globale, oggi ha annunciato i risultati iniziali positivi dallo studio di fase 3 MANGROVE (BGB-3111-306;NCT04002297) volto a valutare l'inibitore fondamentale della tirosin-chinasi di Bruton (BTK) BRUKINSA®(zanubrutinib) in combinazione con rituximab rispetto a bendamustine più rituximab (BR) nei pazienti adulti affetti da linfoma delle cellule mantellari (MCL) non precedentemente trattato.
Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua originale, che è l'unico giuridicamente valido.
Frequently Asked Questions
What are the results of the Phase 3 trial for BRUKINSA?
The Phase 3 trial for BRUKINSA showed positive results as a first-line treatment for MCL.
What type of cancer is BRUKINSA used to treat?
BRUKINSA is used to treat mantle cell lymphoma (MCL).
Who announced the Phase 3 results for BRUKINSA?
BeOne Medicines announced the positive Phase 3 results for BRUKINSA.
What is the significance of the Phase 3 results?
The results indicate BRUKINSA's efficacy, potentially improving treatment options for MCL patients.